The aim of this study was to examine the anti-tumour effects of the clinically representative anti-angiogenic monoclonal antibody bevacizumab combined with the anti-EGFR tyrosine kinase inhibitor erlotinib and RT. This evidence concerns the gene EGFR and neoplasm.